Numerous investigations have documented heightened procoagulant activity in COVID-19 patients, characterized by elevated plasma levels of soluble thrombomodulin, suggesting increased endothelial cell activation, fibrin production, and resistance to fibrinolysis [1]. The gene discussed is THBD; the disease is COVID-19.